title: Serum levels of osteopontin are increased in SIRS and sepsis.
abstract: OBJECTIVE
  In sepsis, dysregulation of the immune response leads to rapid multiorgan failure and death. Accurate and timely diagnosis is lifesaving and should discriminate sepsis from the systemic inflammatory response syndrome (SIRS) caused by non-infectious agents. Osteopontin acts as an extracellular matrix component or a soluble cytokine in inflamed tissues. Its exact role in immune response and sepsis remains to be elucidated. Therefore, we investigated the role of osteopontin in SIRS and sepsis.
  
  
  METHODS
  Prospective, observational study.
  
  
  METHODS
  Intensive care unit of a university hospital.
  
  
  METHODS
  Fifty-six patients with SIRS or sepsis and 56 healthy subjects were enrolled.
  
  
  METHODS
  We analyzed the serum levels of osteopontin and TH1-TH2 cytokines and investigated the role of osteopontin on interleukin 6 secretion by monocytes.
  
  
  RESULTS
  Serum osteopontin levels were strikingly higher in patients than in controls and in sepsis than in SIRS, and decreased during the resolution of both the disorders. Receiver operating characteristic curves showed that osteopontin levels have discriminative power between SIRS and sepsis with an area under the curve of 0.796. Osteopontin levels directly correlated with those of interleukin 6 and in vitro, recombinant osteopontin increased interleukin 6 secretion by monocytes in both the absence and presence of high doses of lipopolysaccharide.
  
  
  CONCLUSIONS
  These data suggest that osteopontin might be a mediator involved in the pathogenesis of SIRS and sepsis, possibly by supporting interleukin 6 secretion.
  
  
  BACKGROUND
  45. SIRS/Sepsis: clinical studies.
authors.affiliation: Department of Clinical and Experimental Medicine, SCDU Anaesthesia and Intensive Care 1, Maggiore della Carità Hospital, "A. Avogadro" University of Eastern Piedmont, Novara, Italy.
authors.forename: Rosanna
authors.initials: R
authors.lastname: Vaschetto
authors.forename: Stefania
authors.initials: S
authors.lastname: Nicola
authors.forename: Carlo
authors.initials: C
authors.lastname: Olivieri
authors.forename: Elena
authors.initials: E
authors.lastname: Boggio
authors.forename: Fabio
authors.initials: F
authors.lastname: Piccolella
authors.forename: Riccardo
authors.initials: R
authors.lastname: Mesturini
authors.forename: Federica
authors.initials: F
authors.lastname: Damnotti
authors.forename: Davide
authors.initials: D
authors.lastname: Colombo
authors.forename: Paolo
authors.initials: P
authors.lastname: Navalesi
authors.forename: Francesco
authors.initials: F
authors.lastname: Della Corte
authors.forename: Umberto
authors.initials: U
authors.lastname: Dianzani
authors.forename: Annalisa
authors.initials: A
authors.lastname: Chiocchetti
mesh_terms: D000328:Adult; D000368:Aged; D015415:Biomarkers / Q000097:blood; D016022:Case-Control Studies; D005260:Female; D006801:Humans; D007362:Intensive Care Units; D015850:Interleukin-6 / Q000097:blood; D008297:Male; D008875:Middle Aged; D053495:Osteopontin / Q000097:blood*; D011446:Prospective Studies; D012372:ROC Curve; D018805:Sepsis / Q000097:blood* / Q000175:diagnosis; D018746:Systemic Inflammatory Response Syndrome / Q000097:blood* / Q000175:diagnosis
chemical_list: D015415:Biomarkers; D015850:Interleukin-6; D053495:Osteopontin